

Genetic Variation in Cytokine-Related Genes and Migraine Susceptibility

Shani Stuart, Bridget H. Maher, Heidi Sutherland, Miles Benton, Astrid Rodriguez, Rod A. Lea, Larisa M. Haupt, and Lyn R. Griffiths

Genomics Research Centre, Griffith Health Institute, Griffith University, Gold Coast Campus, Gold Coast, Queensland, Australia

Migraine is classified by the World Health Organization (WHO) as being one of the top 20 most debilitating diseases. According to the neurovascular hypothesis, neuroinflammation may promote the activation and sensitisation of meningeal nociceptors, inducing the persistent throbbing headache characterized in migraine. The tumor necrosis factor (TNF) gene cluster, made up of TNF α , lymphotoxin α (LTA), and lymphotoxin β (LTB), has been implicated to influence the intensity and duration of local inflammation. It is thought that sterile inflammation mediated by LTA, LTB, and TNF α contributes to threshold brain excitability, propagation of neuronal hyperexcitability and thus initiation and maintenance of a migraine attack. Previous studies have investigated variants within the TNF gene cluster region in relation to migraine susceptibility, with largely conflicting results. The aim of this study was to expand on previous research and utilize a large case-control cohort and range of variants within the TNF gene cluster to investigate the role of the TNF gene cluster in migraine. Nine single nucleotide polymorphisms (SNPs) were selected for investigation as follows: rs1800683, rs2229094, rs2009658, rs2071590, rs2239704, rs909253, rs1800630, rs1800629, and rs3093664. No significant association with migraine susceptibility was found for any of the SNPs tested, with further testing according to migraine subtype and gender also showing no association for disease risk. Haplotype analysis showed that none of the tested haplotypes were significantly associated with migraine.

■ **Keywords:** migraine, inflammation, lymphotoxin α , lymphotoxin β , tumor necrosis factor α , cytokines

Migraine is a severe neurological disorder that causes an intense throbbing or pulsating pain in one area of the head and can be accompanied by nausea, vomiting and extreme photophobia, and phonophobia (Rose & Capildeo, 1983). Migraine is divided into two main categories according to criteria set out by the International Headache Society, namely migraine with aura (MA) and migraine without aura (MO). This disease affects approximately 12% of the Caucasian population, with two-thirds of affected cases being female. Attacks may last up to 72 hours, causing a significant personal burden as well as adversely affecting work productivity. Given the epidemiology of the disease burden, with mainly the economically productive age group being affected, the World Health Organization (WHO) has ranked migraine in the top 20 most debilitating diseases (Leonardi et al., 2005). Despite this significant personal and economic burden of migraine, current treatments are only effective for a proportion of sufferers.

The exact pathophysiology of migraine is still not fully understood and even though a significant proportion of the disease has been attributed to genetic heritability, few

causal genetic variants have been linked to common forms of migraine (Schurks, 2012). For human diseases and other complex traits, heritability can be estimated from the concordance rate between monozygotic and dizygotic twins (Macgregor et al., 2006). Migraine has been shown through twin and family studies to have a significantly heritable component, which has driven genetic studies aimed at identifying causal variants (Colson et al., 2006). Heritability estimates for migraine according to population twin studies range between 0.34 and 0.57 (Mulder et al., 2003; Svensson et al., 2003). While Familial Hemiplegic Migraine (FHM) studies and large migraine Genome-Wide Association Studies (GWAS) have significantly contributed toward our

RECEIVED 18 April 2013; ACCEPTED 30 July 2013. First published online 20 September 2013.

ADDRESS FOR CORRESPONDENCE: Lyn R. Griffiths, Genomics Research Centre, Griffith Health Institute, Griffith University, Gold Coast Campus, Building G05, Griffith University, QLD 4222, Australia. E-mail: l.griffiths@griffith.edu.au

understanding of the possible mechanisms involved in migraine pathogenesis, further research identifying association between migraine susceptibility and common genetic variants is needed (Maher & Griffiths, 2011).

Current theories pertaining to the mechanistic cause of migraine attacks describe a neurovascular mechanism whereby a range of stimuli activate the trigeminal nervous system, causing pain sensitisation via the thalamus. Other theories place more emphasis on a dysfunction between the neuronal nuclei, which in turn modulates sensory inputs (de Almeida et al., 2009; Varlibas & Erdemoglu, 2009). Neurogenic inflammation was found to be a key mechanism in activating the trigeminal nervous system (Moskowitz, 2007). Previously, emphasis has been placed on the idea that vascular and neural stimuli resulting in a wave of neuronal hyperexcitability cause cortical spreading depression (CSD) and consequently a migraine attack. The hypothesis further extends to state that meningeal inflammation occurs as a consequence of CSD and local mediators such as calcitonin gene-related peptide (CGRP), and substance P activates meningeal sensory neurons, causing activation of the pain pathway rather than vasodilation (Buzzi, 2001). However, while CSD has been well documented to cause MA, there is still debate about the importance of CSD in MO (Lauritzen, 1987).

New studies have suggested that migraine pain and trigeminovascular activation are caused by a central mechanism which does not require a primary sensory input (Goadsby & Akerman, 2012; Lambert et al., 2011). The most recent theory describing migraine pathogenesis states that migraine is caused by a dysfunction of the subcortical brain structures including the brainstem and diencephalic nuclei which are involved in modulating sensory inputs. The theory suggests that aura is triggered by dysfunction of these nuclei and that the same mechanism is responsible for the pain and other symptoms experienced during migraine attacks (Akerman et al., 2011).

CGRP is a vasoactive peptide released during migraine attacks and has also been shown to correlate with peripheral trigeminal activation. Trigeminal axons imbedded in blood vessels of the pia mater and dura mater release CGRP among other vasoactive peptides, producing a sterile inflammatory reaction which in part causes the pain of a migraine attack (Buzzi & Moskowitz, 1990; Goadsby et al., 1990). The mechanisms involved in this inflammatory response have long been the target of migraine studies and data have shown that via T-cell stimulation, cytokines are released when CGRP levels are elevated (Cuesta et al., 2002; Levite, 1998). Furthermore, Levy (2009) showed that the release of inflammatory mediators such as cytokines and mast cells, may further promote and sustain the activation and sensitisation of meningeal nociceptors, inducing the persistent throbbing headache characterized in migraine. Given this link as well as the role of cytokines in modulation of pain and sterile inflammation, these molecules have been

proposed as being involved in the pathogenesis of migraine attacks.

Inflammatory Cytokines

Cytokines are signaling molecules that are intricately involved in the activation, differentiation, and control of the immune system. Research has shown that signaling pathways are complex, with many cytokines having multiple functions and acting on different cell types resulting in different functional consequences. Within the broad classification of cytokines, subdivisions are made according to families and subtypes within families (Hiscott & Ware, 2011). The tumor necrosis factor (TNF) super family is a class of molecules most involved with activation and inhibition of inflammatory pathways (Ware, 2011).

Cytokines are constitutively expressed by neurons and glial cells in brain tissue. Known functions of these regulatory molecules include synaptic plasticity, neural transmission, and Ca^{2+} signaling. Calcium signaling is thought to have a significant role in migraine as mutations have been identified in the CACNA1A gene that cause the rare migraine subtype FHM (Ophoff et al., 1996). It has been shown that these mutations can produce gain-of-function $Ca(V)$ 2.1 channels and as a result initiate CSD. The increased activity of the $Ca(V)$ 2.1 channel facilitates increased $Ca(V)$ 2.1-dependent neurotransmitter release from cortical neurons, in particular glutamate (D'Onofrio et al., 2009).

Given the important regulatory role of inflammatory cytokines, especially in the Ca^{2+} signaling pathway, it is biologically feasible for dysregulation of the genes involved in these pathways to cause migraine attacks or at least to lower the threshold for triggering one.

Three of the most studied inflammatory cytokines which are thought to play a role in migraine are $TNF\alpha$, lymphotoxin α (LTA), and lymphotoxin β (LTB). The genes encoding for these products are located in the class III gene cluster of the major histocompatibility complex on chromosome 6 as shown in Figure 1 and variants within these genes have been shown to modulate expression of the corresponding cytokine levels (Bouma et al., 1996; Carroll et al., 1987; Wilson et al., 1997). As seen in Figure 1, the TNF gene cluster is made up of the three genes $TNF\alpha$, LTA, and LTB. It is thought that these three genes are expressed and regulated in a similar fashion to an operon, hence the reference to them making up a gene cluster.

It is well known that $TNF\alpha$ is an important inflammatory cytokine involved in modulation of immune responses and evidence suggests that it also plays a role in migraine. Biochemical studies have shown that changes in serum and urine concentrations of $TNF\alpha$ correspond to migraine status of patients (Covelli et al., 1990; Empl et al., 2003; Mueller et al., 2001; Perini et al., 2005). Furthermore, $TNF\alpha$ has been shown to stimulate transcription of CGRP, which is thought to be critical in the migraine pathogenesis pathway




FIGURE 1
(Colour online) Structure of the LTA gene cluster on chromosome 6.

(Durham, 2006). Commonly studied polymorphisms are the 308G>A (rs1800629) variant in the promoter region of TNF α and the 252A>G (rs909253) variant in intron 1 of the TNF α gene.

Other variants within the TNF gene cluster region have also been investigated in relation to migraine susceptibility, with conflicting results (Asuni et al., 2006; Ghosh et al., 2010; Mazaheri et al., 2006; Rainero et al., 2004; Schurks et al., 2009; Trabace et al., 2002). Of particular interest was a study conducted in a Korean population, where rs2844482 located in the LTA gene was found to be significantly ($p = .0003$) associated with migraine (Lee et al., 2007). A recent meta-analysis examined the overall association between migraine susceptibility and variants within the TNF gene cluster for a large number of published studies. The authors found no overall association between any of the investigated gene variants and migraine including its subtypes, despite pre-existing biological plausibility. However, most of the studies included in the meta-analysis consisted of small cohorts. The authors suggested that a larger case-control study compared to a single small cohort may provide more statistical power and clarify the potential role of the TNF gene cluster in migraine (Schurks et al., 2011). A recent pedigree Genome-Wide Association Study (pGWAS) conducted in the genetic isolate Norfolk Island population supports this notion, with five variants within the TNF gene cluster found to be nominally significant (Cox, 2011; Cox et al., 2012). Three of these variants within the LTA gene namely rs2009658, rs2844482, and rs2229094 that have been

subsequently investigated in an outbred Australian Caucasian population (Oikari et al., 2012), however, showed no association with migraine susceptibility.

Given the conflicting nature of the prior studies and the findings by Lee et al. (2007) that haplotypes within the LTA gene demonstrated association with migraine, further investigation of other variants in the LTA gene and additional variants within the TNF gene cluster in a larger case-control cohort was warranted to clarify the involvement of genetic variation in this region. The aim of this study is to expand on previous studies conducted and utilize a larger case-control cohort in addition to investigating a larger range of variants within the TNF gene cluster, specifically in the LTA gene.

Materials and Methods

Sample Selection

Migraine cases and controls were recruited from the local South East Queensland region through the Genomics Research Centre (GRC) outpatient clinic, through various methods including media coverage and advertisements, as well as referral by neurologists (Colson et al., 2004). They were all of Caucasian origin, and diagnosed as having MA or MO based on criteria specified by the International Headache Society. Each participant was required to fill out standardized questionnaires outlining frequency and severity of migraine attacks as well as family history. This information was used to make a diagnosis. An unaffected control group with no family history of migraine was matched

for age (+/- 5 years), sex, and ethnicity. Blood samples obtained from patients were collected through the GRC clinic and DNA was extracted using a salting out method. Approval for the study protocol was acquired from the Griffith University's Ethics Committee for Experimentation on Humans. A total of 736 samples were genotyped for nine variants found within the LTA and TNF α genes as follows: rs1800683, rs2229094, rs2009658, rs2071590, rs2239704, rs909253, rs1800630, rs1800629, and rs3093664. Of these 736 samples, 192 samples were genotyped for the single nucleotide polymorphisms (SNPs) rs2229094 and rs2009658 in a previous study (Oikari et al., 2012). The remaining 544 samples were genotyped for the first time for these variants. The other seven SNPs selected were not genotyped previously in any of the 736 samples. One SNP previously genotyped, namely rs2844482, was not included due to incompatibility in the SNP plex designed for Sequenom.

Molecular Analysis

Matrix-assisted desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry was used to genotype each sample in a multiplexed reaction (Shchepinov et al., 2001). The Sequenom instrument and accompanying software were used to carry out all genotyping work as well as the design of amplification and genotyping primers. In this approach, unique primer pairs were designed to amplify each region of interest such that only one region would be amplified for each primer pair. A genotyping primer was then designed to anneal directly adjacent to the SNP of interest, allowing for enzymatic extension of a single dideoxy base pair following polymerase chain reaction amplification. The extended primer was then robotically dispensed onto a silicon chip preloaded with matrix, ionized and released. The time-of-flight was recorded for each fragment, which has a slightly different density according to genotype and interpreted as a scatter plot. Genotyping was confirmed independently using either high-resolution melt (HRM) analysis (rs2229094) or restriction fragment length polymorphism (RFLP) analysis (rs2009658; Oikari et al., 2012).

Statistical Analysis

Of the 736 samples genotyped, 25 samples failed due to poor quality (3%) and 26 samples were included as duplicate or triplicate controls of other samples. Genotyping of these samples was removed prior to analysis after confirmation that genotyping results matched across samples. After filtering, 685 genotyped individuals remained, which included 167 males and 518 females divided into 340 unique cases and 345 controls.

SPSS was used to perform a basic allelic association analysis using a χ^2 test, comparing the allele frequencies of migraine cases to controls for each SNP investigated. Hardy-Weinberg equilibrium (HWE) was calculated for each SNP to check for genotyping error and an α value of 0.005 was

set as the significance threshold to correct for multiple tests. Migraine cases were further subdivided and compared to controls according to the subtypes MA and MO. Analysis according to sex was also performed. The odds ratio was calculated with a 95% confidence interval as an indication of disease risk. The minor allele frequency was calculated and compared to European HapMap frequencies. Haploview was used to determine linkage disequilibrium (LD) blocks across the two genes investigated.

Results

HWE calculations showed that each SNP was in HWE in both cases and controls, except for one SNP, rs1800629, which gave a *P* value of .04 in the case samples. Given that the deviation from HWE was so small and also that the accuracy of genotyping results was confirmed through independent HRM and RFLP analysis, these data were still included in our analysis.

Allele frequencies for both cases and controls were compared to HapMap European population data, and there are no significant differences between frequency values. Genotyping results showed that the variants tested for in our Australian Caucasian population occur at similar frequencies compared to other European populations.

An allelic association test showed that the allele frequencies were not significantly different between overall migraine cases and controls for all nine SNPs tested. When migraine was analyzed according to subtype, no significant difference was found between MA compared to controls and MO compared to controls for any of the SNPs tested, as illustrated in Table 1. No significant association was found between migraine susceptibility and sex. The odds ratios calculated for each test did not convey a significant risk or protective effect for migraine susceptibility for any of the SNPs tested. Gender and migraine subtype also was not found to influence disease risk for the nine SNPs tested.


Haplotype analysis using Haploview showed that of the nine variants tested, eight were in almost complete LD, as illustrated in Figure 2. Markers were grouped into two haplotype blocks, with block one containing eight of the nine markers. Association testing according to haplotype revealed no significant association between migraine and any of the haplotypes as shown in Table 2.

Discussion

Both IL-1 and TNF α are well-studied cytokines in the field of molecular medicine (Feuerstein et al., 1994; Hiscott & Ware, 2011). Particularly, popular choices in migraine susceptibility studies include these molecules in addition to variants found within the TNF gene cluster. Previous studies have shown that both TNF α and LTA could be susceptibility genes in migraine, and it has been suggested that other functional polymorphisms that influence migraine risk could be in LD with some of these variants. However, studies have

TABLE 1Association Between $LT\alpha$ and $TNF\alpha$ Variants and Migraine Susceptibility According to Migraine Subtypes, and Migraine Overall

SNP	Migraine overall				Migraine with aura				Migraine without aura			
	MAF		χ^2 (p value)	OR (L95–U95)	MAF		χ^2 (p value)	OR (L95–U95)	MAF		χ^2 (p value)	OR (L95–U95)
	Cases	Controls			Cases	Controls			Cases	Controls		
rs2009658	0.15	0.19	2.72 (.09)	0.78 (0.59–1.05)	0.15	0.19	3.33 (.06)	0.74 (0.54–1.02)	0.17	0.19	0.31 (.57)	0.89 (0.60–1.33)
rs2071590	0.33	0.32	0.03 (.85)	1.02 (0.81–1.28)	0.32	0.32	0.003 (.95)	0.99 (0.77–1.28)	0.34	0.32	0.20 (.65)	1.07 (0.78–1.49)
rs1800683	0.39	0.36	2.07 (.15)	1.17 (0.94–1.47)	0.40	0.36	2.15 (.14)	1.20 (0.94–1.54)	0.38	0.36	0.51 (.47)	1.12 (0.82–1.54)
rs2239704	0.36	0.36	0.02 (.87)	1.01 (0.81–1.27)	0.36	0.36	0.0002 (.98)	0.99 (0.78–1.28)	0.37	0.36	0.12 (.72)	1.05 (0.77–1.45)
rs909253	0.39	0.35	1.41 (.23)	1.14 (0.92–1.42)	0.40	0.36	1.83 (.17)	1.18 (0.93–1.51)	0.37	0.36	0.12 (.72)	1.05 (0.77–1.45)
rs2229094	0.27	0.30	1.93 (.16)	0.84 (0.67–1.07)	0.26	0.30	1.81 (.17)	0.83 (0.64–1.09)	0.27	0.30	0.59 (.43)	0.87 (0.62–1.23)
rs1800630	0.15	0.19	2.38 (.12)	0.79 (0.60–1.06)	0.15	0.19	2.38 (.12)	0.77 (0.56–1.07)	0.16	0.19	0.60 (.43)	0.85 (0.56–1.28)
rs1800629	0.20	0.19	0.16 (.68)	1.05 (0.81–1.38)	0.20	0.19	0.20 (.65)	1.07 (0.80–1.44)	0.20	0.19	0.01 (.90)	1.02 (0.70–1.50)
rs3093664	0.09	0.09	0.10 (.74)	0.93 (0.64–1.37)	0.08	0.09	0.27 (.60)	0.89 (0.58–1.37)	0.09	0.09	0.02 (.88)	1.04 (0.61–1.77)

**FIGURE 2**(Colour online) LTA SNPs tested for linkage disequilibrium with results given by D' using Haploview.**TABLE 2**

Haplotype Association Testing Using Haploview

Haplotype	Frequency		χ^2	p
	Cases	Controls		
GTCTTCG	0.311	0.317	0.690	.7928
ATCCGCCA	0.205	0.192	0.400	.5271
ATCCGCCG	0.181	0.158	1.287	.2565
GCGCGTAG	0.152	0.186	2.788	.0949
GCCCGTCG	0.101	0.109	0.204	.6519
GTCCTTCG	0.027	0.030	0.152	.6965

produced conflicting results and have also shown that there are significant differences in allele frequencies of $TNF\alpha$ gene variants between different ethnic groups (Lee et al., 2007; Schurks et al., 2011). A previous study found that while individual SNPs within the TNF gene cluster were not significantly associated with migraine, LTA haplotypes were associated with migraine in the Korean population. Authors also suggested that associations would be best defined in context with the involvement of other genetically linked regions, such as HLA class I loci (Lee et al., 2007).

The aim of this study was to expand on previous studies conducted and investigate previously associated variants as well as other suitable markers within the TNF gene cluster in relation to migraine susceptibility in an Australian Caucasian population. Our selection of nine SNPs across this region allowed for more detailed haplotype analysis, in addition to case-control association analysis. While HWE calculations confirmed genotyping accuracy, no significant association was found with migraine in any of the statistical tests conducted. Our results do, however, illustrate the value of testing multiple markers as multiple SNPs provide more information than single SNPs for the purposes of complex disease mapping. Future studies which examine multiple cytokine family gene variants in conjunction with linked HLA class I haplotypes would be useful.

No significant association was found between the tested variants and migraine susceptibility in this case-control Australian Caucasian population, even when analysis was done in accordance with migraine subtypes and according to haplotypes. This result suggests that either the TNF gene cluster does not play a role in the pathogenesis of migraine, or that it only plays a minor role as part of a more complex

signaling cascade. Given the large diversity of cytokines, it would be useful to examine other families within this broad class of signaling molecules and the role that they may play in sterile inflammation during a migraine attack. A multi-marker analysis approach, making use of other linked HLA regions, would also provide better insight into the role of cytokines during the inflammation process. A meta-analysis that incorporates all the studies conducted to date would also be a useful tool to conclude whether any of the TNF markers are associated with migraine.

A number of large GWAS aiming to identify associations between genetic variants and migraine have been conducted, with the first being published by the International Headache Genetics Consortium (IHGC) in 2010 (Anttila et al., 2010; Schurks, 2012). Two subsequent GWAS conducted by the Dutch-Icelandic migraine genetics consortium (DICE) and the Women's Genome Health Study (WGHS) failed to replicate the results from the first GWAS and only identified modest associations (Ligthart et al., 2011). However, a large meta-analysis of all the cohorts identified three new SNPs showing significance at the genome-wide level, namely rs2651899, rs10166942, and rs11172113 located in intron 1 of PRDM16, 2q37 near TRPM8 and intron 1 of LRP1, respectively (Chasman et al., 2011).

Thus far, SNPs in the TNF gene cluster have not shown genome-wide significance in these large GWAS. However, given the complex inheritance and the gene-environment interactions known to occur for complex diseases, a very large sample size would be required before variants with small effects are detected. More targeted family linkage studies and association studies could provide a useful approach for detecting variants with small to moderate effects on migraine susceptibility. Gene expression studies have shown significant changes in expression of TNF for menstrual migraineurs, so while association could be limited to specific subtypes of migraine, future studies are still relevant (Mueller et al., 2001).

Acknowledgments

This work was funded by an NHMRC grant. Contributing authors were supported by Australian Post-graduate Award (APA) scholarships and Griffith University Postgraduate Award (GUPA) scholarships.

References

- Akerman, S., Holland, P. R., & Goadsby, P. J. (2011). Diencephalic and brainstem mechanisms in migraine. *Nature Reviews. Neuroscience*, 12, 570–584.
- Anttila, V., Stefansson, H., Kallela, M., Todt, U., Terwindt, G. M., Calafato, M. S., . . . Palotie, A. (2010). Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *Nature Genetics*, 42, 869–873.
- Asuni, C., Stochino, M. E., Cherchi, A., Manconi, M., Congiu, D., & Del Zompo, M. (2006). Migraine and tumor necrosis factor gene polymorphism: An association study in a Sardinian sample. *Journal of Neurology*, 256, 194–197.
- Bouma, G., Crusius, J. B., Oudkerk Pool, M., Kolkman, J. J., von Blomberg, B. M., Kostense, P. J., . . . Pena, A. S. (1996). Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. *Scandinavian Journal of Immunology*, 43, 456–463.
- Buzzi, M. G. (2001). Trigeminal pain pathway: Peripheral and central activation as experimental models of migraine. *Functional Neurology*, 16, 77–81.
- Buzzi, M. G., & Moskowitz, M. A. (1990). The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. *British Journal of Pharmacology*, 99, 202–206.
- Carroll, M. C., Katzman, P., Alicot, E. M., Koller, B. H., Geraghty, D. E., Orr, H. T., . . . Spies, T. (1987). Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. *Proceedings of the National Academy of Sciences of the United States of America*, 84, 8535–8539.
- Chasman, D. I., Schurks, M., Anttila, V., de Vries, B., Schminke, U., Launer, L. J., . . . Kurth, T. (2011). Genome-wide association study reveals three susceptibility loci for common migraine in the general population. *Nature Genetics*, 43, 695–698.
- Colson, N. J., Lea, R. A., Quinlan, S., & Griffiths, L. R. (2006). The role of vascular and hormonal genes in migraine susceptibility. *Molecular Genetics and Metabolism*, 88, 107–113.
- Colson, N. J., Lea, R. A., Quinlan, S., MacMillan, J., & Griffiths, L. R. (2004). The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. *Neurogenetics*, 5, 129–133.
- Covelli, V., Munno, I., Pellegrino, N. M., Di Venere, A., Jirillo, E., & Buscaino, G. A. (1990). Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with migraine without aura. *Acta neurologica*, 12, 257–263.
- Cox, H. (2011). *Genetic analysis of complex disease in the Norfolk Island Bounty mutineer descendants*. Doctoral dissertation (unpublished). Griffith University, Gold Coast, Australia.
- Cox, H. C., Lea, R. A., Bellis, C., Carless, M., Dyer, T. D., Curran, J., . . . Griffiths, L. R. (2012). A genome-wide analysis of 'Bounty' descendants implicates several novel variants in migraine susceptibility. *Neurogenetics*, 13, 261–266.
- Cuesta, M. C., Quintero, L., Pons, H., & Suarez-Roca, H. (2002). Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. *Neurochemistry International*, 40, 301–306.
- D'Onofrio, M., Ambrosini, A., Di Mambro, A., Arisi, I., Santorelli, F. M., Grieco, G. S., . . . Buzzi, M. G. (2009). The interplay of two single nucleotide polymorphisms in the CACNA1A gene may contribute to migraine susceptibility. *Neuroscience Letters*, 453, 12–15.

- de Almeida, R. F., Leao, I. A. T., Gomes, J. B. L., da Silva, A. A., & Teixeira, A. L. (2009). Migraine with persistent visual aura: Response to furosemide. *Clinics*, *64*, 375–376.
- Durham, P. L. (2006). Calcitonin gene-related peptide (CGRP) and migraine. *Headache*, *46*, S3–S8.
- Empl, M., Sostak, P., Riedel, M., Schwarz, M., Muller, N., Forderreuther, S., & Straube, A. (2003). Decreased sTNF-RI in migraine patients? *Cephalalgia*, *23*, 55–58.
- Feuerstein, G. Z., Liu, T., & Barone, F. C. (1994). Cytokines, inflammation, and brain injury — role of tumor-necrosis-factor-alpha. *Cerebrovascular and Brain Metabolism Reviews*, *6*, 341–360.
- Ghosh, J., Joshi, G., Pradhan, S., & Mittal, B. (2010). Investigation of TNFA 308G > A and TNFB 252G > A polymorphisms in genetic susceptibility to migraine. *Journal of Neurology*, *257*, 898–904.
- Goadsby, P. J., & Akerman, S. (2012). The trigeminovascular system does not require a peripheral sensory input to be activated — migraine is a central disorder. Focus on ‘effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system’. *Cephalalgia*, *32*, 3–5.
- Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. *Annals of Neurology*, *28*, 183–187.
- Hiscott, J., & Ware, C. (2011). Cytokines. *Current Opinion in Immunology*, *23*, 561–563.
- Lambert, G. A., Truong, L., & Zagami, A. S. (2011). Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. *Cephalalgia*, *31*, 1439–1451.
- Lauritzen, M. (1987). Cerebral blood-flow in migraine and cortical spreading depression. *Acta Neurologica Scandinavica*, *76*, 9–40.
- Lee, K. A., Jang, S. Y., Sohn, K. M., Won, H. H., Kim, M. J., Kim, J. W., & Chung, C. S. (2007). Association between a polymorphism in the lymphotoxin — a promoter region and migraine. *Headache*, *47*, 1056–1062.
- Leonardi, M., Steiner, T. J., Scher, A. T., & Lipton, R. B. (2005). The global burden of migraine: Measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). *The Journal of Headache and Pain*, *6*, 429–440.
- Levite, M. (1998). Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, *95*, 12544–12549.
- Levy, D. (2009). Migraine pain, meningeal inflammation, and mast cells. *Current Pain and Headache Reports*, *13*, 237–240.
- Ligthart, L., de Vries, B., Smith, A. V., Ikram, M. A., Amin, N., Hottenga, J. J., . . . Boomsma, D. I. (2011). Meta-analysis of genome-wide association for migraine in six population-based European cohorts. *European Journal of Human Genetics*, *19*, 901–907.
- Macgregor, S., Cornes, B. K., Martin, N. G., & Visscher, P. M. (2006). Bias, precision and heritability of self-reported and clinically measured height in Australian twins. *Human Genetics*, *120*, 571–580.
- Maher, B. H., & Griffiths, L. R. (2011). Identification of molecular genetic factors that influence migraine. *Molecular Genetics and Genomics*, *285*, 433–446.
- Mazaheri, S., Hajilooi, M., & Rafiei, A. (2006). The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura. *Journal of Neurology*, *253*, 1589–1593.
- Moskowitz, M. A. (2007). Pathophysiology of headache — past and present. *Headache*, *47*, S58–S63.
- Mueller, L., Gupta, A. K., & Stein, T. P. (2001). Deficiency of tumor necrosis factor alpha in a subclass of menstrual migraineurs. *Headache*, *41*, 129–137.
- Mulder, E. J., Van Baal, C., Gaist, D., Kallela, M., Kaprio, J., Svensson, D. A., . . . Palotie, A. (2003). Genetic and environmental influences on migraine: A twin study across six countries. *Twin Research*, *6*, 422–431.
- Oikari, L. E., Stuart, S., Okolicsanyi, R. K., Cox, H. C., Dixit, S., Lea, R. A., . . . Griffiths, L. R. (2012). Investigation of lymphotoxin alpha genetic variants in migraine. *Gene*, *512*, 527–531.
- Ophoff, R. A., Terwindt, G. M., Vergouwe, M. N., van Eijk, R., Oefner, P. J., Hoffman, S. M., . . . Frants, R. R. (1996). Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4. *Cell*, *87*, 543–552.
- Perini, F., D’Andrea, G., Galloni, E., Pignatelli, F., Billo, G., Alba, S., . . . Toso, V. (2005). Plasma cytokine levels in migraineurs and controls. *Headache*, *45*, 926–931.
- Rainero, I., Grimaldi, L. M. E., Salani, G., Valfre, W., Rivoiro, C., Savi, L., & Pinessi, L. (2004). Association between the tumor necrosis factor-alpha-308 G/A gene polymorphism and migraine. *Neurology*, *62*, 141–143.
- Rose, F. C., & Capildeo, R. (1983). Migraine: Definition and classification. *Cephalalgia*, *3*, 225–229.
- Schurks, M. (2012). Genetics of migraine in the age of genome-wide association studies. *The Journal of Headache and Pain*, *13*, 1–9.
- Schurks, M., Kurth, T., Buring, J. E., & Zee, R. Y. L. (2009). A candidate gene association study of 77 polymorphisms in migraine. *Journal of Pain*, *10*, 759–766.
- Schurks, M., Rist, P. M., Zee, R. Y. L., Chasman, D. I., & Kurth, T. (2011). Tumour necrosis factor gene polymorphisms and migraine: A systematic review and meta-analysis. *Cephalalgia*, *31*, 1381–1404.
- Shchepinov, M. S., Denissenko, M. F., Smylie, K. J., Worl, R. J., Leppin, A. L., Cantor, C. R., & Rodi, C. P. (2001). Matrix-induced fragmentation of P3’-N5’ phosphoramidate-containing DNA: High-throughput MALDI-TOF analysis of genomic sequence polymorphisms. *Nucleic Acids Research*, *29*, 3864–3872.
- Svensson, D. A., Larsson, B., Waldenlind, E., & Pedersen, N. L. (2003). Shared rearing environment in migraine: Results from twins reared apart and twins reared together. *Headache*, *43*(3), 235–244.

- Trabace, S., Brioli, G., Lulli, P., Morellini, M., Giacobazzo, M., Ciciarelli, G., & Martelletti, P. (2002). Tumor necrosis factor gene polymorphism in migraine. *Headache*, 42, 341–345.
- Varlibas, A., & Erdemoglu, A. K. (2009). Altered trigeminal system excitability in menstrual migraine patients. *The Journal of Headache and Pain*, 10, 277–282.
- Ware, C. F. (2011). The TNF receptor super family in immune regulation. *Immunological Reviews*, 244, 5–8.
- Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., & Duff, G. W. (1997). Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proceedings of the National Academy of Sciences of the United States of America*, 94, 3195–3199.
-